CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

21 Live Marks
49 on record
AG
First Filed:Apr 11, 2018Latest Filed:Oct 23, 2026Address:Baarerstrasse 14, ZUG V8, 6300, CH

Portfolio Overview

Top Classes

Class 5
Pharmaceuticals
32(65%)
Class 42
Software, IT Services & Scientific Research
23(47%)
Class 41
Education and Entertainment
11(22%)

TTAB Proceedings

Proceedings
4
As Plaintiff
4(100%)
As Defendant
0(0%)
Extensions of Time
2

Top Firms

MARSHALL, GERSTEIN & BORUN L...(Oct 2026)
48
Collen IP Intellectual Prope...(Feb 2019)
1

Trademark Activity Timeline(2018 – 2026)

Trademark Portfolio

49 results

(current & previous marks)

Refine by Mark/Description🔽
Filed
Registered
Last Activity
INTEGRACAR-T
INTEGRACAR-T
Trademark
Word
PENDING
Owner:
Serial:50177838
Filed:Oct 23, 2026
Classes:1, 5, 40, +1
Description: Class 1: Delivery vehicles, namely, targeted lipid nanoparticles (tLNPs) carrying chimeric antigen receptor (CAR)-encoding nucleic acids for in vivo, ex vivo, or in vitro scientific research and medical research; Delivery vehicles, namely, targeted lipid nanoparticles (tLNPs) carrying chimeric antigen receptor (CAR)-encoding nucleic acids for use in the manufacture of pharmaceuticals for treating cancers, inflammatory disorders, immunoregulatory disorders, autoimmune disorders, metabolic disorders and infectious disorders
Class 5: Medical, biological and pharmaceutical preparations for scientific, research, medical, or pharmaceutical use, namely, preparations for treating cancers, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders; medical, biological and pharmaceutical preparations containing polypeptide or chimeric antigen receptor (CAR) encoding nucleic acids for the prevention and treatment of rare diseases, cancers, inflammatory disorders, immunoregulatory disorders, autoimmune disorders, metabolic disorders, and infectious disorders; RNA-based therapeutics and therapeutic agents, and delivery vehicles, namely, targeted lipid nanoparticles (tLNPs) carrying chimeric antigen receptor (CAR)-encoding nucleic acids, for in vitro preparation and in vivo or ex vivo delivery to cell sites outside or inside an organism; Medical diagnostic reagents
Class 40: Custom biomanufacturing of pharmaceutical drug substances and drug products
Class 42: Conducting clinical trials for others; Scientific research and development in the field of targeted lipid nanoparticles (tLNPs) carrying chimeric antigen receptor (CAR)-encoding nucleic acids for treating cancers, inflammatory disorders, immunoregulatory disorders, autoimmune disorders, metabolic disorders and infectious disorders; Scientific research and development in the field of RNA-based therapeutics and therapeutic agents; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy.
CTX213
CTX213
Trademark
Word
ABANDONED
Owner:
Serial:99582999
Filed:Jan 7, 2026
Classes:5, 42
Description: Class 5: Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of diabetes; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of diabetes
Class 42: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development
CTX321
CTX321
Trademark
Word
PENDING
Owner:
Serial:99583004
Filed:Jan 7, 2026
Classes:5, 42
Description: Class 5: Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy
Class 42: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
CTX611
CTX611
Trademark
Word
PENDING
Owner:
Serial:99583006
Filed:Jan 7, 2026
Classes:5, 42
Description: Class 5: Cells for medical or clinical use in the field of gene therapy for the treatment of cardiovascular diseases and thromboembolic diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy
Class 42: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of gene therapy
CRISPR-X
CRISPR-X
Service Mark
Word
PENDING
Owner:
Serial:99555280
Filed:Dec 18, 2025
Classes:42
Description: Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development in the field of gene editing, delivery and formulation; medical research laboratory services; scientific laboratory services; custom cell-line engineering services for scientific research purposes; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals
CTX460
CTX460
Trademark
Word
PENDING
Owner:
Serial:99434958
Filed:Oct 9, 2025
Classes:5, 42
Description: Class 5: Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of lung and liver diseases or conditions; pharmaceutical and biopharmaceutical agents for the treatment of lung and liver diseases or conditions in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of lung and liver diseases or conditions in the field of in vivo gene editing therapy
Class 42: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
SYNTASE
SYNTASE
Service Mark
Word
PENDING
Owner:
Serial:99421485
Filed:Sep 30, 2025
Classes:42
Description: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy; Research in the field of gene editing technology; Providing a gene editing platform for others to conduct pharmaceutical research and development in the field of in vivo gene editing therapy
CTX213
CTX213
Trademark
Word
PENDING
Owner:
Serial:98955696
Filed:Jan 13, 2025
Classes:5, 42
Description: Cells for medical or clinical use in the field of stem cell therapy for the treatment of diabetes; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of diabetes; pharmaceutical and biopharmaceutical agents for the treatment of diabetes; gene editing, namely, pharmaceutical research and development in the field of stem cell therapy for the treatment of diabetes; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of stem cell therapy for the treatment of diabetes
CTX340
CTX340
Trademark
Word
PENDING
Owner:
Serial:98589121
Filed:Jun 6, 2024
Classes:5, 42
Description: Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of renal and cardiovascular diseases or conditions; pharmaceutical and biopharmaceutical agents for the treatment of renal and cardiovascular diseases or conditions in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of renal and cardiovascular diseases or conditions in the field of in vivo gene editing therapy; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
CTX450
CTX450
Trademark
Word
PENDING
Owner:
Serial:98589124
Filed:Jun 6, 2024
Classes:5, 42
Description: Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of liver, neurological, and neurovascular diseases or conditions; pharmaceutical and biopharmaceutical agents for the treatment of liver, neurological, and neurovascular diseases or conditions in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of liver, neurological, and neurovascular diseases or conditions in the field of in vivo gene editing therapy; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
CTX211
CTX211
Trademark
Word
ABANDONED
Owner:
Serial:98347437
Filed:Jan 8, 2024
Classes:5
CRISPR-X
CRISPR-X
Service Mark
Combined
REGISTERED
Owner:
Serial:98247548
Filed:Oct 31, 2023
Classes:42
Registration:8524563
Registered:Oct 27, 2026
Description: Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development, namely, providing medical and scientific research and development in the fields of pharmaceuticals and biopharmaceuticals; medical research laboratory services; scientific laboratory services; custom cell-line engineering services for scientific research purposes; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals
CRISPR THERAPEUTICS
CRISPR THERAPEUTICS
Trademark
Combined
REGISTERED
Owner:
Serial:98164705
Filed:Sep 5, 2023
Classes:5, 41, 42
Registration:7701014
Registered:Feb 25, 2025
Description: Education services, namely, providing online non-downloadable articles and newsletters in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical products and preparations, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of genetic diseases and disorders; Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development, namely, providing medical and scientific research and development in the fields of pharmaceuticals and biopharmaceuticals; medical research laboratory services; scientific laboratory services; custom cell-line engineering services for scientific research purposes; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals
CRISPR THERAPEUTICS
CRISPR THERAPEUTICS
Trademark
Word
REGISTERED
Owner:
Serial:98164704
Filed:Sep 5, 2023
Classes:5
Registration:7701013
Registered:Feb 25, 2025
Description: Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical products and preparations, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of genetic diseases and disorders
CRISPR THERAPEUTICS DE&I IT'S IN OUR DNA DIVERSITY, EQUITY, AND INCLUSION
Owner:
Serial:97635376
Filed:Oct 17, 2022
Classes:41
CRISPR THERAPEUTICS DE&I IT'S IN OUR DNA. DIVERSITY, EQUITY, AND INCLUSION
Owner:
Serial:97635380
Filed:Oct 17, 2022
Classes:41
Description: "DE&I" AND "DIVERSITY, EQUITY, AND INCLUSION"
CTX130
CTX130
Trademark
Word
ABANDONED
Owner:
Serial:97635360
Filed:Oct 17, 2022
Classes:5
DE&I IT'S IN OUR DNA
DE&I IT'S IN OUR DNA
Service Mark
Word
ABANDONED
Owner:
Serial:97635372
Filed:Oct 17, 2022
Classes:41
DIVERSITY, EQUITY, AND INCLUSION IT'S IN OUR DNA
Owner:
Serial:97635364
Filed:Oct 17, 2022
Classes:41
CRISPRX
CRISPRX
Service Mark
Word
ABANDONED
Owner:
Serial:97558002
Filed:Aug 22, 2022
Classes:42
Description: Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals
CTX330
CTX330
Trademark
Word
ABANDONED
Owner:
Serial:97469034
Filed:Jun 21, 2022
Classes:5, 42
Description: Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
CTX121
CTX121
Trademark
Word
ABANDONED
Owner:
Serial:97461207
Filed:Jun 16, 2022
Classes:5
CTX310
CTX310
Trademark
Word
REGISTERED
Owner:
Serial:97461217
Filed:Jun 16, 2022
Classes:5, 42
Registration:8005333
Registered:Oct 28, 2025
Description: Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
CTX320
CTX320
Trademark
Word
REGISTERED
Owner:
Serial:97461218
Filed:Jun 16, 2022
Classes:5, 42
Registration:8137672
Registered:Feb 10, 2026
Description: Class 5: Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy
Class 42: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
VCTX212
VCTX212
Trademark
Word
ABANDONED
Owner:
Serial:97461144
Filed:Jun 16, 2022
Classes:5
PEC-211
PEC-211
Trademark
Word
ABANDONED
Owner:
Serial:97459057
Filed:Jun 15, 2022
Classes:5
VCTX211
VCTX211
Trademark
Word
ABANDONED
Owner:
Serial:97459047
Filed:Jun 15, 2022
Classes:5
VCTX211-DF
VCTX211-DF
Trademark
Word
ABANDONED
Owner:
Serial:97459070
Filed:Jun 15, 2022
Classes:5
VCTX211-ST
VCTX211-ST
Trademark
Word
ABANDONED
Owner:
Serial:97459065
Filed:Jun 15, 2022
Classes:5
CTX112
CTX112
Trademark
Word
REGISTERED
Owner:
Serial:97371562
Filed:Apr 20, 2022
Classes:5, 42
Registration:8137640
Registered:Feb 10, 2026
Description: Class 5: Cells for medical or clinical use in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases; pharmaceutical and biopharmaceutical agents for the treatment of cancer in the field of CAR T cell therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer in the field of CAR T cell therapy
Class 42: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases; gene editing, namely, pharmaceutical research and development in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases
CTX131
CTX131
Trademark
Word
ABANDONED
Owner:
Serial:97371566
Filed:Apr 20, 2022
Classes:5, 42
Description: Cells for medical or clinical use in the field of CAR T cell therapy for the treatment of hematologic malignancies; pharmaceutical and biopharmaceutical agents for the treatment of cancer in the field of CAR T cell therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer in the field of CAR T cell therapy; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of CAR T cell therapy for the treatment of hematologic malignancies; gene editing, namely, pharmaceutical research and development in the field of CAR T cell therapy for the treatment of hematologic malignancies
VCTX210
VCTX210
Trademark
Word
ABANDONED
Owner:
Serial:97371557
Filed:Apr 20, 2022
Classes:5
COBALT
COBALT
Trademark
Word
ABANDONED
Owner:
Serial:90722349
Filed:May 19, 2021
Classes:5
CRISPR THERAPEUTICS
CRISPR THERAPEUTICS
Service Mark
Word
REGISTERED
Owner:
Serial:90715256
Filed:May 17, 2021
Classes:41, 42
Registration:6724517
Registered:May 24, 2022
Description: Class 41: Education services, namely, providing on-line non-downloadable articles and newsletters in the field of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy
Class 42: Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals
AVOLANCHE
AVOLANCHE
Trademark
Word
ABANDONED
Owner:
Serial:90696824
Filed:May 7, 2021
Classes:9
AVOLANCHE
AVOLANCHE
Trademark
Combined
ABANDONED
Owner:
Serial:90696814
Filed:May 7, 2021
Classes:9
GUIDESPACE
GUIDESPACE
Service Mark
Word
ABANDONED
Owner:
Serial:88524528
Filed:Jul 19, 2019
Classes:42
CRISPRTX
CRISPRTX
Service Mark
Word
ABANDONED
Owner:
Serial:88509950
Filed:Jul 11, 2019
Classes:41
CTX110
CTX110
Trademark
Word
REGISTERED
Owner:
Serial:88296694
Filed:Feb 11, 2019
Classes:5, 42
Registration:6760727
Registered:Jun 14, 2022
Description: Class 5: Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer
Class 42: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development
CTX120
CTX120
Trademark
Word
ABANDONED
Owner:
Serial:88296736
Filed:Feb 11, 2019
Classes:5
CTX130
CTX130
Trademark
Word
ABANDONED
Owner:
Serial:88296767
Filed:Feb 11, 2019
Classes:5
CRISPR COLLECTIVE CC
CRISPR COLLECTIVE CC
Service Mark
Stylized
ABANDONED
Owner:
Serial:88292462
Filed:Feb 7, 2019
Classes:41
CRISPR COLLECTIVE
CRISPR COLLECTIVE
Service Mark
Word
CANCELLED
Owner:
Serial:87871992
Filed:Apr 11, 2018
Classes:41
Registration:5910676
Registered:Nov 12, 2019
Description: Education services, namely, providing online non-downloadable articles and newsletters in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy
CRISPR THERAPEUTICS
CRISPR THERAPEUTICS
Service Mark
Word
REGISTERED
Owner:
Serial:87980024
Filed:Apr 11, 2018
Classes:41, 42
Registration:5916961
Registered:Nov 19, 2019
Description: Education services, namely, providing online non-downloadable articles and newsletters in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy | Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals
CRISPR THERAPEUTICS
CRISPR THERAPEUTICS
Service Mark
Combined
REGISTERED
Owner:
Serial:87980023
Filed:Apr 11, 2018
Classes:41, 42
Registration:5916960
Registered:Nov 19, 2019
Description: Education services, namely, providing online non-downloadable articles and newsletters in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy | Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development services relating to targeting genetic therapies to individuals
CRISPR THERAPEUTICS
CRISPR THERAPEUTICS
Trademark
Combined
REGISTERED
Owner:
Serial:87872064
Filed:Apr 11, 2018
Classes:5
Registration:6055218
Registered:May 12, 2020
Description: Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical products and preparations, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of genetic diseases and disorders
CRISPR THERAPEUTICS
CRISPR THERAPEUTICS
Trademark
Word
REGISTERED
Owner:
Serial:87872234
Filed:Apr 11, 2018
Classes:5
Registration:6055219
Registered:May 12, 2020
Description: Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer, infectious disease, autoimmune disorders, transplant rejections and inflammatory disease; pharmaceutical products and preparations, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of genetic diseases and disorders
CTX001
CTX001
Trademark
Word
ABANDONED
Owner:
Serial:87872108
Filed:Apr 11, 2018
Classes:5
CTX101
CTX101
Trademark
Word
ABANDONED
Owner:
Serial:87872157
Filed:Apr 11, 2018
Classes:5